EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

HBeAg clearance in chronic Hepatitis B: is it predictable?

Tuba İlgar, Aybegüm Özşahin, Sudem Mahmutoğlu Çolak, İlknur Esen Yıldız, Uğur Kostakoğlu, Ayşe Ertürk

The Journal of Infection in Developing Countries · 2025

DOI: 10.3855/jidc.20784 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infection in Developing Countries, 2025. Verfasst von Tuba İlgar und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Recep Tayyip Erdoğan University, Rize, Türkiye. Hauptthemen laut MEDLINE: Hepatitis B, Chronic, Hepatitis B e Antigens, Antiviral Agents. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Prediction of HBeAg loss is crucial for understanding the prognosis of chronic hepatitis B (CHB) and determining when to discontinue treatment. We aimed to identify factors predicting HBeAg clearance in patients undergoing antiviral treatment for HBeAg-positive CHB Methodology: This retrospective study included patients who started antiviral treatment for HBeAg-positive CHB from January 1, 2008, to December 31, 2022, with at least one year of follow-up. We evaluated age, platelet count, treatment duration, ALT × Upper limit of normal (ULN), AST × ULN, AST/ALT ratio, Albumin-Bilirubin grade (ALBI), Platelet-Albumin-Bilirubin grade (PALBI), AST-Platelet ratio index (APRI), and Fibrosis-4 (FIB-4) parameters. ROC analysis was used to assess these parameter's ability to predict HBeAg loss.

Results

Ninety-four patients were included, 43 (45.7%) of whom were female. HBeAg clearance occurred in 32 (34%) patients. Treatment duration was significantly longer in patients with HBeAg clearance (p = 0.003). Patients with HBeAg clearance had significantly higher median age, fibrosis score (FS), APRI, and FIB-4 values (p = 0.028, p = 0.024, p = 0.008, and p = 0.003, respectively) and lower mean platelet count (p = 0.010) at treatment initiation. ROC analysis identified age, FS, APRI, FIB-4, and platelet count as significant predictors, with APRI having the highest area under the curve (AUC = 0.771, p = 0.007, sensitivity 65%, specificity 66.7% for the cut-off value of 0.71).

Conclusions

This study highlights the potential of FIB-4, platelet count, and particularly APRI in predicting HBeAg clearance. These findings can aid clinicians in optimizing treatment strategies and improving patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis B, ChronicHepatitis B e AntigensAntiviral AgentsHumansFemaleMaleRetrospective StudiesAdultMiddle AgedYoung AdultROC CurvePlatelet CountPrognosis

Stichwörter der Autor:innen

APRIAntiviralFIB-4HBeAg clearance

Substanzen

Hepatitis B e AntigensAntiviral Agents

Autor:innen und Institutionen

  • Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Recep Tayyip Erdoğan University, Rize, Türkiye.
  • Department of Infectious Diseases and Clinical Microbiology, Recep Tayyip Erdoğan University Training and Research Hospital, Rize, Türkiye.

Zitieren

APA

İlgar, T., Özşahin, A., Mahmutoğlu Çolak, S., Yıldız, İ. E., Kostakoğlu, U., & Ertürk, A. (2025). HBeAg clearance in chronic Hepatitis B: is it predictable?. The Journal of Infection in Developing Countries. https://doi.org/10.3855/jidc.20784

Vancouver

İlgar T, Özşahin A, Mahmutoğlu Çolak S, Yıldız İE, Kostakoğlu U, Ertürk A. HBeAg clearance in chronic Hepatitis B: is it predictable?. The Journal of Infection in Developing Countries. 2025. doi:10.3855/jidc.20784

BibTeX
@article{lgar2025,
  author = {İlgar, Tuba and Özşahin, Aybegüm and Mahmutoğlu Çolak, Sudem and Yıldız, İlknur Esen and Kostakoğlu, Uğur and Ertürk, Ayşe},
  title = {HBeAg clearance in chronic Hepatitis B: is it predictable?},
  journal = {The Journal of Infection in Developing Countries},
  year = {2025},
  doi = {10.3855/jidc.20784}
}
Kostenlos starten →